학술논문
Final Results of the RHAPSODY Trial: A Multi-Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A-APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke.
Document Type
Journal Article
Author
Lyden, Patrick; Pryor, Kent E.; Coffey, Christopher S.; Cudkowicz, Merit; Conwit, Robin; Jadhav, Ashutosh; Sawyer, Robert N.; Claassen, Jan; Adeoye, Opeolu; Song, Shlee; Hannon, Peter; Rost, Natalia S.; Hinduja, Archana; Torbey, Michel; Lee, Jin‐Moo; Benesch, Curtis; Rippee, Michael; Rymer, Marilyn; Froehler, Michael T.; Clarke Haley, E.
Source
Subject
*PROTEIN C
*STROKE treatment
*TISSUE plasminogen activator
*STROKE patients
*THROMBOLYTIC therapy
*DRUG dosage
*DRUG tolerance
*MEDICATION safety
*
*
*
*
*
*
*
Language
ISSN
0364-5134
Abstract